S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:BTAI

BioXcel Therapeutics (BTAI) Stock Price, News & Analysis

$2.82
-0.06 (-2.08%)
(As of 03/28/2024 ET)
Today's Range
$2.79
$2.91
50-Day Range
$1.95
$4.04
52-Week Range
$1.91
$29.56
Volume
335,500 shs
Average Volume
685,548 shs
Market Capitalization
$86.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.86

BioXcel Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
497.8% Upside
$16.86 Price Target
Short Interest
Healthy
14.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.13
Upright™ Environmental Score
News Sentiment
0.69mentions of BioXcel Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.28) to ($1.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.34 out of 5 stars

Medical Sector

129th out of 938 stocks

Pharmaceutical Preparations Industry

54th out of 432 stocks

BTAI stock logo

About BioXcel Therapeutics Stock (NASDAQ:BTAI)

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BTAI Stock Price History

BTAI Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Two words health boss wants scrapped
Q4 2023 BioXcel Therapeutics Inc Earnings Call
Here's what Wall Street expects from BioXcel Therapeutics's earnings
See More Headlines
Receive BTAI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2023
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BTAI
Fax
N/A
Employees
183
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$16.86
High Stock Price Target
$40.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+497.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

Net Income
$-179,050,000.00
Net Margins
-12,974.86%
Pretax Margin
-12,974.86%

Debt

Sales & Book Value

Annual Sales
$1.38 million
Book Value
$2.74 per share

Miscellaneous

Free Float
19,630,000
Market Cap
$86.24 million
Optionable
Optionable
Beta
0.42

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Vimal D. Mehta Ph.D. (Age 62)
    Founder, CEO, President, & Director
    Comp: $1.76M
  • Mr. Javier Rodriguez (Age 51)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $638.88k
  • Mr. Matthew Wiley (Age 51)
    Senior VP & Chief Commercial Officer
    Comp: $620.12k
  • Mr. Richard I. Steinhart MBA (Age 67)
    Senior VP & CFO
    Comp: $404k
  • Dr. Frank D. Yocca Ph.D. (Age 67)
    Senior VP & Chief Scientific Officer
    Comp: $452.58k
  • Dr. Vincent J. O'Neill B.Sc. (Age 55)
    M.D., M.R.C.P., Executive VP, Chief of Product Development & Medical Officer
    Comp: $510.17k
  • Dr. Chetan D. Lathia Ph.D.
    Senior VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs
  • Dr. Robert Risinger M.D.
    Chief Medical Officer - Neuroscience
  • Mr. Robert Scala (Age 55)
    Vice President of Commercial Operations & Launch Planning
  • Dr. Friso Postma
    Senior Director of Neuroscience & Artificial intelligence

BTAI Stock Analysis - Frequently Asked Questions

Should I buy or sell BioXcel Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BTAI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BTAI, but not buy additional shares or sell existing shares.
View BTAI analyst ratings
or view top-rated stocks.

What is BioXcel Therapeutics' stock price target for 2024?

7 equities research analysts have issued 12 month price objectives for BioXcel Therapeutics' stock. Their BTAI share price targets range from $4.00 to $40.00. On average, they expect the company's share price to reach $16.86 in the next twelve months. This suggests a possible upside of 497.8% from the stock's current price.
View analysts price targets for BTAI
or view top-rated stocks among Wall Street analysts.

How have BTAI shares performed in 2024?

BioXcel Therapeutics' stock was trading at $2.95 at the start of the year. Since then, BTAI shares have decreased by 4.4% and is now trading at $2.82.
View the best growth stocks for 2024 here
.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 3,140,000 shares, a drop of 20.9% from the February 29th total of 3,970,000 shares. Based on an average trading volume of 1,530,000 shares, the short-interest ratio is currently 2.1 days. Approximately 14.6% of the company's shares are sold short.
View BioXcel Therapeutics' Short Interest
.

When is BioXcel Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BTAI earnings forecast
.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) issued its quarterly earnings data on Monday, August, 14th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.72) by $0.11. The company earned $0.46 million during the quarter, compared to analysts' expectations of $0.42 million. BioXcel Therapeutics had a negative trailing twelve-month return on equity of 2,941.56% and a negative net margin of 12,974.86%. The company's quarterly revenue was up 45600.0% on a year-over-year basis. During the same period in the previous year, the company earned ($1.35) EPS.

What ETF holds BioXcel Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 2,477 shares of BTAI stock, representing 0.39% of its portfolio.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology (MRVL), Invitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

When did BioXcel Therapeutics IPO?

BioXcel Therapeutics (BTAI) raised $60 million in an IPO on Thursday, March 8th 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.59%), Vanguard Group Inc. (3.59%), Charles Schwab Investment Management Inc. (0.63%), Citadel Advisors LLC (0.00%), Pennant Investors LP (0.28%) and Virtu Financial LLC (0.20%). Insiders that own company stock include Bioxcel Llc, Frank Yocca, Javier Rodriguez, Krishnan Nandabalan, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends
.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BTAI) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners